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Background: No consensus exists on how to define abnormally rapid deterioration in renal function (Rapid
Progression, RP). We developed an operational definition of RP in HIV-positive persons with baseline estimated
glomerular filtration rate (eGFR) >90 ml/min/1.73 m2 (using Cockcroft Gault) in the Data Collection on Adverse
Events of Anti-HIV Drugs (D:A:D) study from 2004 to 2011.
Methods: Two definitions were evaluated; RP definition A: An average eGFR decline (slope) ≥5 ml/min/1.73 m2/
year over four years of follow-up with ≥3 eGFR measurements/year, last eGFR <90 ml/min/1.73 m2 and an absolute
decline ≥5 ml/min/1.73 m2/year in two consecutive years. RP definition B: An absolute annual decline ≥5 ml/min/
1.73 m2/year in each year and last eGFR <90 ml/min/1.73 m2. Sensitivity analyses were performed considering two
and three years’ follow-up. The percentage with and without RP who went on to subsequently develop incident
chronic kidney disease (CKD; 2 consecutive eGFRs <60 ml/min/1.73 m2 and 3 months apart) was calculated.
Results: 22,603 individuals had baseline eGFR ≥90 ml/min/1.73 m2. 108/3655 (3.0%) individuals with ≥4 years’
follow-up and ≥3 measurements/year experienced RP under definition A; similar proportions were observed when
considering follow-up periods of three (n=195/6375; 3.1%) and two years (n=355/10756; 3.3%). In contrast under RP
definition B, greater proportions experienced RP when considering two years (n=476/10756; 4.4%) instead of three
(n=48/6375; 0.8%) or four (n=15/3655; 0.4%) years’ follow-up. For RP definition A, 13 (12%) individuals who
experienced RP progressed to CKD, and only (21) 0.6% of those without RP progressed to CKD (sensitivity 38.2%
and specificity 97.4%); whereas for RP definition B, fewer RP individuals progressed to CKD.
Conclusions: Our results suggest using three years’ follow-up and at least two eGFR measurements per year is most
appropriate for a RP definition, as it allows inclusion of a reasonable number of individuals and is associated with
the known risk factors. The definition does not necessarily identify all those that progress to incident CKD, however,
it can be used alongside other renal measurements to early identify and assess those at risk of developing CKD.
Future analyses will use this definition to identify other risk factors for RP, including the role of antiretrovirals.
Keywords: HIV, Kidney disease, Rapid progression, Estimated glomerular filtration rate, Chronic kidney disease* Correspondence: d.kamara@ucl.ac.uk; lrn@cphiv.dk
†Equal contributors
1Research Dept. of Infection and Population Health, University College
London, London, United Kingdom
2Department of Infectious Diseases and Rheumatology, Rigshospitalet,
University of Copenhagen, CHIP, Section 2100, Finsencentret, Copenhagen,
Denmark
Full list of author information is available at the end of the article
© 2014 Kamara et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Kamara et al. BMC Nephrology 2014, 15:51 Page 2 of 13
http://www.biomedcentral.com/1471-2369/15/51Background
Whilst most HIV-positive individuals have a relatively
stable renal function over time, some experience a rapid
deterioration in their estimated glomerular filtration rate
(eGFR) [1-5]. It is important to identify and assess such
individuals and potential risk factors, especially those as-
sociated with known risk factors for renal insufficiency.
These patients are usually difficult to identify, because
as soon as their eGFR decreases, but still remains within
a clinically acceptable range, most physicians will switch
to non-nephrotoxic antiretroviral drugs [2]. Thus, devel-
oping a validated definition of an eGFR slope could guide
future studies.
Studying those with initially normal renal function (de-
fined by the Kidney Disease Improving Global Outcomes
[KDIGO] as eGFR ≥90 ml/min/1.73 m2 [6]) who experi-
ence a rapid decline in their renal function is important,
as it could potentially detect kidney impairment at an
early stage, before manifest kidney disease has occurred
[7,8]. A study from the Modification of Diet in Renal
Disease (MDRD) study group, to determine baseline fac-
tors that predict the decline in GFR, made a case for rapid
decline in renal function to be further investigated. They
reported that the mean rate of GFR decline was not
significantly related to the baseline GFR, and this suggests
an approximately linear mean eGFR decline as renal dis-
ease progresses [9]. Rapid progression (RP), an abnormally
rapid deterioration in renal function, is a term commonly
used in the renal literature. However, unlike CKD (typic-
ally defined as two consecutive eGFRs ≤60 ml/min/
1.73 m2 measured more than 3 months apart), it is with-
out a standardised definition. It is commonly accepted
that a normal age-related eGFR decline in the general
population (typically >50 years) is approximately 1 ml/
min/1.73 m2/year [10-12]. Therefore, any definition of RP
should consider larger changes, and ≥3 ml/min/1.73 m2
has been commonly used [13-18]. However, it is unclear
whether a decline of this magnitude is specific enough to
accurately identify those at greatest risk of going on
to develop CKD. Recent KDIGO guidelines suggest that,
for those with evidence of CKD, RP should be defined as a
sustained decline of >5 ml/min/1.73 m2 per year [12], al-
though no definition is offered for those with normal
baseline renal function. Other definitions of RP have also
been used, including a >50% decrease in baseline eGFR
value [19].
The length of time over which an eGFR decline should
be sustained to qualify as RP is also unclear [18]. Further-
more, individuals can have differing numbers of eGFR
measurements recorded over follow-up. It remains unclear
how these multiple measurements have been accounted
for; whether an average annual change (i.e. the averaged
slope across all available eGFR measurements for an
individual, or the average of several yearly changes)or an absolute change over a time period (i.e. the differ-
ence between first and last eGFR measurements) has been
calculated. This variation in RP definitions limits the abil-
ity to make cross-study comparisons.
HIV-positive persons are at increased risk of renal dys-
function compared to the HIV negative population [1-5],
potentially due to high prevalence of traditional renal risk
factors [20,21], toxicity from specific antiretroviral drugs
[2] and HIV infection itself [5]. As HIV-positive individuals
in resource rich settings typically undergo regular renal
function testing in accordance with standard screening
guidelines, a standardised definition of RP for this popula-
tion could be beneficial. Therefore, we developed an op-
erational definition for RP in HIV-positive individuals
by evaluating the associations between these definitions
and traditional renal risk factors. Finally, we investigated
the ability of the different definitions to predict future in-
cident CKD.
Methods
Study population
The D:A:D study is a large observational multi-cohort col-
laboration of HIV- positive individuals from 11 cohorts in
Europe, USA and Australia [22]. All participating cohorts
have obtained ethical approval and, if appropriate, in-
formed consent, as required by national guidelines and
regulations. Of particular interest to this present analysis,
all creatinine measurements on study participants taken
as part of routine care from the date of D:A:D study entry
onwards were collected. Data were available from nine
contributing cohorts. Only measurements taken after 1st
January 2004, the date from which monitoring of creatin-
ine levels was routine across these nine cohorts, were in-
cluded in this analysis.
EGFR calculation
As some of the cohorts in the D:A:D study are prohib-
ited from collecting data on participants’ ethnicity, the
Cockroft-Gault (CG) formula was used [23-25], stan-
dardized for body surface area (BSA), as has been done
in a previous D:A:D analysis [2]. The closest weight meas-
urement within 12 months of the date of the creatinine
measurement was used, alongside height and current age.
Where more than one serum creatinine value was mea-
sured within 28 days, the median value and mean date
across this time period were used.
Included study populations
We identified 22,603 D:A:D study participants with at
least three eGFR measurements after 1 January 2004
whose first (baseline) eGFR was ≥90 ml/min/1.73 m2.
We then assessed the proportion of this initial popu-
lation that would be eligible to be included in a study
of RP, depending on the individuals’ length of available
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surements per year (≥2 or ≥3) required.
RP definition
We next developed two definitions of RP (definition A
and definition B). We first considered the study popula-
tion with at least four years of follow-up, and at least
three eGFR measurements in each year. We decided that
a relatively large annual decline in eGFR ≥5 ml/min/
1.73 m2 per year would constitute RP. This was to avoid
‘noise’ introduced by natural eGFR fluctuations, based
on advice from nephrologists and in line with the re-
cent KDIGO guidelines [12]. We hypothesised that a
RP definition that only considered the difference be-
tween the first and last eGFR value (the “absolute de-
cline”) may be too susceptible to random eGFR variation.
However, a definition that only considers the modelled
decline (i.e. fitting a linear slope to all eGFR measure-
ments during follow-up to estimate the average annual
eGFR change) may also not fully capture RP, as nega-
tive eGFR changes might be compensated by subse-
quent positive changes, and so our definition captured
both elements. In addition, as the clinical implications
of RP within normal eGFR ranges are unknown, we re-
stricted our definition to include only those that pro-
gressed to an eGFR value below <90 ml/min/1.73 m2.
This led to our primary definition of RP (Figure 1) as
defined below.
RP: definition a (RPA; Figure 1)
Individuals were considered to have experienced RP over
the four year period if they met all of the following three
conditions:
1. Average annual eGFR decline ≥5 ml/min/1.73 m2
over four year follow-up period.
2. Absolute eGFR decline ≥5 ml/min/1.73 m2 in two
consecutive years (defined using the first and last
measurements within each year).75
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Figure 1 RP definition A.3. eGFR <90 ml/min/1.73 m2 at the end of the
follow-up period.
Secondary definition for RP: definition B (RPB; Figure 2)
Individuals were considered to have experienced RP
under the more restrictive definition B (Figure 2) if the
following criteria were met:
1. Absolute decline ≥5 ml/min/1.73 m2/year in each
year of follow-up (defined on the basis of the first
and last measurements within each year).
2. eGFR <90 ml/min/1.73 m2 at the end of the
follow-up period.
Alternative RP definitions
The analyses were repeated using different follow-up
periods (three and two years instead of four years) and re-
striction on the number of measurements per year required
to be eligible for inclusion in the analysis (≥2 measure-
ments/year instead of ≥3 measurements/year).
Statistical methods
Baseline was defined as the date of first eGFR measure-
ment after 1 January 2004. Logistic regression models
were used to assess the association between the different
RP definitions and well established traditional renal risk
factors - age, hypertension and diabetes [23-29]. The aim
was to ensure that the definition of RP eventually chosen
was a suitable compromise between maximising the num-
ber of persons eligible to be assessed for RP and the stron-
gest risk factor associations. The C-Statistic was used to
determine how well the logistic regression models dis-
criminate between those who experience RP and those
who do not. The C-statistic takes values between 0.5 to 1,
where 0.5 corresponds to the worst discriminant model
(one that performs no better than chance), and 1 corre-
sponds to a model that perfectly discriminates between in-
dividuals with and without the outcome [30].75
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Figure 2 RP definition B.
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Gender and ethnicity were only considered in additional
multivariable logistic regression models, both due to
limited numbers of women and individuals of non-
Caucasian origin, and also due to conflicting reports
about the extent to which these factors are independent
predictors of rapid decline in eGFR [10,11,19,28,31-33].
We also considered a composite endpoint of RP and all-
cause mortality. Finally we investigated the number of
individuals who would be considered to have RP if a
3 ml/min/1.73 m2 decline was considered instead of
5 ml/min/1.73 m2.
Additional analyses
To check the robustness of our main and alternative RP
definitions, we investigated the number of individuals
considered to have experienced RP under each definition
that went on to develop CKD. Follow-up started at the
end of the time period used to define whether an indi-
vidual experienced RP or not, and any events after this
time were considered.
Results
Of 24,799 individuals with normal baseline eGFR, 22,603
(9.1%) had at least three eGFR measurements after 1
January 2004 and could potentially be assessed for RP. A total
of 22,603 individuals had normal baseline eGFR ≥90 ml/
min/1.73 m2, with at least three eGFR measurements after
1 January 2004 and could potentially be assessed for RP.
The median number of measurements and length of
follow-up was 12 (interquartile range (IQR) 7–16)) and
4.6 (IQR 2.7-6.1) years respectively. The median number
of eGFR measurements available per individual per year
was 3 (IQR 2–3) years.
Baseline characteristics
Table 1 shows the baseline characteristics of individuals
included in the analysis. Most of the 22,603 individuals
eligible for inclusion in the analysis were male (72.7%),
of Caucasian (46.8%) or unknown ethnicity (43.0%), less
than 50 years old (90.1%), with BMI in the range of ≥18
to <26 kg/m2 (70.2%), current smokers (42.2%) or ex-
smokers (17.4%) and with a current CD4 count ≥350
cell/mm3 (65.1%).
There were 13,061 individuals with at least four years
follow-up, and of these 3,655 (16.2% of the original 22,603
participants) had ≥3 measurements/year and 8,298 (36.7%)
had ≥2 measurements/year. There were 16,165 individuals
with at least three years of follow-up; of these 6,375
(28.2%) had ≥3 measurements/year, and 12,283 (54.3%)
had ≥2 measurements/year (Table 1). Finally, 19,309 indi-
viduals had at least two years of follow-up; 10,756
(47.6%) had ≥3 measurements/year, and 17,211 (76.1%)
had ≥2 measurements/year (Additional file 1: Table S1).The characteristics of those eligible for assessment for RP
using the primary definition were similar to all included
(Table 1), as for the other RP definitions based on varying
follow-up periods and number of eGFR measurements/
year.
Percentage experiencing RP
The average rate of eGFR decline for all participants
was −3.91 ml/min/1.73 m2 /year (95% confidence
interval; −11.7, 3.8 ml/min/1.73 m2/year). Of the 3,655 in-
dividuals with ≥ 4 four years’ follow-up and ≥3 measure-
ments/year, 108 (3.0%; Figure 3) experienced RP according
to definition A. Similar proportions were considered to
have experienced RP when considering shorter follow-up
periods of three years (195/6375; 3.1%) and two years
(355/10756; 3.3%). In contrast under RP definition B, con-
siderably greater proportions were considered to have ex-
perienced RP regardless of whether two (476/10756; 4.4%),
three (48/6375; 0.8%) or four (15/3655; 0.4%) years’ follow-
up was considered.
When two annual eGFR measurements were required
instead of three, similar proportions experienced RP
under definition A, irrespective of the length of follow-up
period (256/8298 (3.1%) experienced RP using four years
follow-up, 369/12283 (3.0%) using three years follow-up,
and 602/17211 (3.5%) using two years follow-up). The
same was also true for RP definition B. Thus, it appears
that the requirement for two or three eGFR measure-
ments per year did not impact greatly on the proportion
of individuals considered to be rapid progressors. When
using a decline of 3 ml/min/1.73 m2 instead of 5 ml/min/
1.73 m2 to define RP, the percentage of individuals that
progressed to RP increased as expected across all strata
(Figure 3).
Association between traditional renal risk factors and
rapid progression (RP)
In a multivariable logistic regression, the odds ratios
(OR) for the association between age >50 years and RP
were strong for every definition (Table 2); they varied
between 1.90 to 2.54 for the primary definition (RP def-
inition A) and between 2.55 to 2.80 for RP definition B.
In contrast, there was more variation for the association
with hypertension, and the strength depended on the
length of follow-up. No associations between hyperten-
sion and RP were found when two years of follow-up
was considered (the ORs varied between 0.99 and 1.14),
whereas for three and four years of follow-up an associ-
ation was generally found, although not all reached statistical
significance at the 5% level. No RP definition demonstrated
a clear association with diabetes (ORs varied between 0.48
to 1.24).
The C-Statistics for these logistic regression models
were very similar in magnitude, ranging from 0.56 to
Table 1 Baselinea characteristics of patients included in analyses of rapid progression, according to availability of data
Patients
with eGFR data
available
≥4 years follow-up ≥3 years follow-up
Unrestrictedf ≥3 eGFR per year ≥2 eGFR
per year
Unrestricted* ≥3 eGFR
per year
≥2 eGFR
per year
Eligible patients Number (%) 22603 (100) 13061 (57.8) 3655 (16.2) 8298 (36.7) 16165 (71.5) 6375 (28.2) 12283 (54.3)
Average eGFR Median (IQR) 109 (99–123) 108 (99–122) 107 (98–121) 108 (99–121) 109 (99–122) 108 (99–122) 108 (99–122)
eGFR >120 ml/min Number (%) 6613 (29.3) 3616 (27.7) 943 (26) 225 (27) 4562 (28.1) 1723 (27) 3412 (28)
Gender Male 16438 (72.7) 9335 (71.5) 2622 (71.7) 5999 (72.3) 11613 (71.8) 4617 (72.4) 8906 (72.5)
Race White 10573 (46.8) 6343 (48.6) 1631 (44.6) 3835 (46.2) 7469 (46.2) 2584 (40.5) 5454 (44.4)
Black 1806 (8.0) 1141 (8.7) 354 (9.7) 720 (8.7) 1346 (8.3) 581 (9.1) 1023 (8.3)
Other 510 (2.3) 306 (2.3) 103 (2.8) 197 (2.4) 385 (2.4) 155 (2.4) 294 (2.4)
Unknown 9714 (43.0) 5271 (40.4) 1567 (42.9) 3546 (42.7) 6965 (43.1) 3055 (47.9) 5512 (44.9)
Age group >50 years 2238 (9.9) 1280 (9.8) 410 (11.2) 868 (10.5) 1641 (10.2) 702 (11.0) 1309 (10.7)
Hypertensionb Yes 2519 (11.1) 1526 (11.7) 494 (13.5) 1030 (12.4) 1865 (11.5) 784 (12.3) 1458 (11.9)
Diabetesc Yes 659 (2.9) 428 (3.3) 145 (4.0) 290 (3.5) 517 (3.2) 237 (3.7) 413 (3.4)
Mode of HIV
acquisition
Homosexual 10006 (44.3) 5642 (43.2) 1611 (44.1) 3710 (44.7) 7028 (43.5) 2876 (45.1) 5487 (44.7)
IDU 3058 (13.5) 1783 (13.7) 450 (12.3) 1019 (12.3) 2196 (13.6) 740 (11.6) 1540 (12.5)
Heterosexual 8095 (35.8) 4865 (37.3) 1385 (37.9) 3081 (37.1) 5952 (36.8) 2359 (37.0) 4499 (36.6)
Other 1444 (6.4) 771 (5.9) 209 (5.7) 488 (5.9) 989 (6.1) 400 (6.3) 757 (6.2)
BMI at study
entry (kg/m2)
<18 633 (2.8) 345 (2.6) 91 (2.5) 216 (2.6) 440 (2.7) 169 (2.7) 330 (2.7)
≥18, <26 15865 (70.2) 9310 (71.3) 2542 (69.6) 5877 (70.8) 11473 (71.0) 4466 (70.1) 8717 (71.0)
≥26, <30 3716 (16.4) 2231 (17.1) 677 (18.5) 1466 (17.7) 2727 (16.9) 1106 (17.4) 2088 (17.0)
≥30 1423 (6.3) 845 (6.5) 238 (6.5) 536 (6.5) 1037 (6.4) 398 (6.2) 774 (6.3)
Unknown 966 (4.3) 330 (2.5) 107 (2.9) 203 (2.5) 488 (3.0) 236 (3.7) 374 (3.0)
Hepatitis Cd positive Yes 2765 (12.2) 1605 (12.3) 400 (10.9) 910 (11.0) 1958 (12.1) 653 (10.2) 1346 (10.6)
Hepatitis Be positive Yes 2773 (12.3) 1551 (12.4) 450 (12.3) 1001 (12.1) 1971 (12.2) 816 (12.8) 1501 (12.2)
Smoking status Current 9544 (42.2) 5554 (42.5) 1467 (40.1) 3445 (41.5) 6930 (42.9) 2571 (40.3) 5198 (42.3)
Previous 3930 (17.4) 2426 (18.6) 681 (18.6) 1557 (18.8) 2923 (18.1) 1193 (18.7) 2248 (18.3)
Never 5824 (25.8) 3599 (27.6) 1086 (29.7) 2332 (28.1) 4314 (26.7) 1726 (27.1) 3299 (26.9)
Unknown 3305 (14.6) 1482 (11.4) 421 (11.5) 964 (11.6) 1998 (12.4) 885 (13.9) 1538 (12.5)
Current CD4 count
(cells/mm3)
<200 2823 (12.5) 1435 (11.0) 482 (13.2) 940 (11.3) 1831 (11.3) 833 (13.1) 1424 (11.6)
200-349 4912 (21.7) 2797 (21.4) 826 (22.6) 1807 (21.8) 3427 (21.2) 1444 (22.7) 2641 (21.5)
350-499 5565 (24.6) 3294 (25.2) 963 (26.4) 2109 (25.4) 4049 (25.1) 1632 (25.6) 3078 (25.1)
≥500 9145 (40.5) 5492 (42.1) 1371 (37.5) 3417 (41.2) 6779 (41.9) 2432 (38.2) 5079 (41.4)
Missing 158 (0.7) 43 (0.3) 13 (0.4) 25 (0.3) 79 (0.5) 34 (0.5) 61 (0.5)
Abbreviations: eGFR, estimated glomerular filtration rate; IDU, injecting drug user;
aBaseline was defined as the defined as the time, during prospective follow-up, of the first eGFR measurement on or after 1 January 2004.
bHypertension was defined as a blood pressure of ≥150/≥100 mmHg or use of antihypertensive drugs and ace inhibitors.
cDiabetes was defined as receipt of antidiabetic treatment or verification of diabetes in a case report form.
dHepatitis C was defined as detection of antibody to HCV plus detection or unknown presence of HCV RNA.
eHepatitis B was defined as detection of HBV surface antigen, detection of HBV e antigen, or detection of HBV DNA plus antibody to HBV e antigen.
fUnrestricted was defined as no restriction concerning the number of eGFR measurements obtained per year.
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and ethnicity to these models did not substantively change
the results (results not shown). The composite endpoint of
RP and mortality markedly increased the number of events
as expected, but the association with age and hyperten-
sion in the logistic regression remained similar (results
not shown).Progression to CKD
For the primary definition of RP (definition A with
4 years’ follow-up and at least 3 measurements per year),
13 (12%) individuals who experienced RP progressed to
CKD by the end of the follow-up period (i.e. the test
had a positive predictive value [PPV] of 12%), whereas
only 21 (0.6%) of those without RP progressed to CKD
Years of follow-up 4 4 3 3 2 2 4 4 3 3 2 2
Measurements per year 3 2 3 2 3 2 3 2 3 2 3 2
N with event, definition A 108 256 195 369 355 602 218 506 325 602 527 885
N with event, definition B 15 43 85 173 476 779 37 97 151 292 633 1021
N in study population 3655 8298 6375 12283 10756 17211 3655 8298 6375 12283 10756 17211
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Figure 3 Proportion of patients that satisfy different RP definitions, for decline of 5 or 3 ml/min/1.73 m2.
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0.6%, or NPV = 99.4%; Table 3). These values corre-
sponded to sensitivity and specificity for the primary def-
inition of 38.2% and 97.4%, suggesting RP from initial
normal eGFR levels is not a good marker for subsequent
CKD, within the timeframes analysed in this study. As theTable 2 Associations$ between different rapid progression of
risk factors
With at least three eGFR measurements
Years of
follow-up
Baseline
variables
RP definition A RP defin
OR (95% CI) P OR (95% C
Four Age >50 years 1.90 (1.15-3.14) 0.01
*Hypertension 1.42 (0.85-2.37) 0.19
Diabetes 1.06 (0.44-2.54) 0.90
Three Age >50 years 1.91 (1.31-2.77) <0.001 2.75 (1.64-4
Hypertension 1.58 (1.08-2.33) 0.02 1.31 (0.71-
Diabetes 0.91 (0.45-1.83) 0.64 1.16 (0.45-
Two Age >50 years 2.32 (1.78-3.04) <0.001 2.70 (2.15-3
Hypertension 1.09 (0.80-1.50) 0.58 1.14 (0.87-
Diabetes 0.92 (0.53-1.61) 0.78 0.73 (0.43-
RP definition A: First eGFR >90; average slope during follow-up ≥5 per year; absolut
RP definition B: First eGFR >90; absolute decline ≥5 in all years of follow-up; last eG
$Results from multivariable logistic regression analysis.
*Insufficient numbers experiencing RP with this definition.definition of RP became less restrictive (with fewer years
of follow-up and number of eGFR measurements/year),
fewer of those who experienced RP progressed to CKD
(PPV estimates decreased from 12% to 3.3%), whereas the
proportion of those not experiencing RP, who did progress
to CKD remained constant (1-NPV varied from 0.4% torenal function definitions and traditional renal disease
With at least two eGFR measurements
ition B RP definition A RP definition B
I) P OR (95% CI) P OR (95% CI) P
2.33 (1.69-3.20) <0.001 2.65 (1.27-5.53) 0.01
1.41 (1.00-1.97) 0.05 1.31 (0.55-3.10) 0.54
0.88 (0.47-1.60) 0.68 0.48 (0.06-3.62) 0.48
.59) <0.001 2.07 (1.58-2.71) <0.001 2.80 (1.95-4.04) <0.001
2.40) 0.39 1.39 (1.04-1.85) 0.03 0.79 (0.49-1.28) 0.34
3.00) 0.76 0.94 (0.56-1.59) 0.82 1.24 (0.62-2.51) 0.54
.39) <0.001 2.54 (2.06-3.12) <0.001 2.55 (2.07-3.14) <0.001
1.49) 0.36 0.99 (0.78-1.27) 0.96 1.00 (0.78-1.28) 0.99
1.23) 0.24 1.14 (0.67-1.95) 0.62 0.98 (0.64-1.51) 0.93
e decline ≥5 in two consecutive years; last eGFR <90.
FR <90.
Table 3 Percentage who progressed to incident CKD*, according to different definitions of RP
Years of
follow-up
considered
Number
of eGFR
per year
Excluded in
analysis
RP definition A RP definition B
aRP (PPV) bnon-RP (1-NPV) Sensitivity (%) Specificity (%) RP (PPV) non-RP (1-NPV) Sensitivity (%) Specificity (%)
Declines of >5 ml/min/1.73 m2 required to meet the RP definition
Four Three 65/18948 (0.3) 13/108(12.0) 21/3547 (0.6) 38.2 97.4 0/15 (0.0) 34/3640 (0.9) 0.0 99.6
Four Two 42/14305 (0.3) 23/256 (9.0) 34/8042 (0.4) 40.4 97.2 2/43 (4.7) 55/8255 (0.7) 3.5 99.5
Three Three 47/16228 (0.3) 15/195 (7.7) 37/6180 (0.6) 28.8 97.2 4/85 (4.7) 48/6290 (0.8) 7.7 98.7
Three Two 24/10320 (0.2) 20/369 (5.4) 55/11914 (0.5) 26.7 97.1 7/173 (4.1) 68/12110 (0.6) 9.3 98.6
Two Three 28/11847 (0.2) 14/355 (3.9) 57/10401 (0.6) 19.7 96.8 16/476 (3.4) 55/10280 (0.5) 22.5 95.7
Two Two 7/5392 (0.1) 20/602 (3.3) 72/16609 (0.4) 21.7 96.6 23/779 (3.0) 69/16432 (0.4) 25.0 95.6
Declines of >3 ml/min/1.73 m2 required to meet the RP definition
Four Three 65/18948 (0.3) 18/218 (8.3) 16/3437 (0.5) 52.9 94.5 3/37 (8.1) 31/3618 (0.9) 8.8 99.1
Four Two 42/14305 (0.3) 27/506 (5.3) 30/7792 (0.4) 47.4 94.2 6/97 (6.2) 51/8201 (0.6) 10.5 98.9
Three Three 47/16228 (0.3) 21/325 (6.5) 31/6050 (0.5) 40.4 95.2 8/151 (0.7) 44/6224 (27.5) 15.4 97.7
Three Two 24/10320 (0.2) 25/602 (4.2) 50/11681 (0.4) 33.3 95.3 14/292 (4.8) 61/11991 (0.5) 18.7 97.7
Two Three 28/11847 (0.2) 20/527 (3.8) 51/10229 (0.5) 28.2 95.3 22/633 (2.8) 49/10123 (0.5) 31.0 94.3
Two Two 7/5392 (0.1) 30/885 (3.4) 62/16326 (0.4) 32.6 95.0 32/1021(4.5) 60/16190 (0.4) 34.8 94.2
*Two consecutive eGFR measurements <60 ml/min/1.73 m2.
aRP: Rapid Progressors who developed CKD (i.e., the positive predictive value (PPV)).
bNon-RP: non-Rapid Progressors who developed CKD (i.e., 1-negative predictive value (NPV)).
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mates were generally smaller compared to obtained from
definition A, and the specificity and (1-NPV) estimates
were similar. When using an eGFR decline of 3 instead of
5 ml/min/1.73 m2 to define RP, the proportion that pro-
gressed to CKD (i.e. the PPV) decreased (Table 3). Much
weaker associations were seen when an endpoint of CKD
or death was considered (Additional file 2: Table S2).
Discussion
This manuscript considered an operational definition of
RP in HIV-positive individuals. Our results suggest a
definition that would apply to individuals with normal
baseline eGFR (≥90 ml/min/1.73 m2) with at least three
years’ follow-up and at least two eGFR measurements
per year, for the reasons described in subsequent para-
graphs. Rapid progressors are defined as those who had:
(i) an average decline over the three-year period of ≥5 ml/
min/m2 per year, (ii) an eGFR decline ≥5 ml/min/1.73 m2
in two consecutive years and (iii) an eGFR at the end of
the three year period of <90 ml/min/1.73 m2 (RP defin-
ition A). This definition allows inclusion of a reasonable
number of individuals that are broadly representative of
the study cohort. It also had reasonable discriminatory
ability to identify those who would go on to develop
incident CKD, although none demonstrated particularly
strong prognostic ability. However, as follow up after hav-
ing experienced RP is still relatively short, later studies will
show if those experiencing RP will be at higher risk of
CKD and mortality in the longer term [34].
In deriving a definition for RP, we considered an an-
nual decline ≥5 ml/min/1.73 m2 instead of the ≥3 ml/
min/1.73 m2 decline as previously reported [13-18]. This
ensured that only clinically relevant events were identi-
fied by reducing the impact of the “noise” that is intro-
duced by random variability in eGFR measurements [9]
and secondly this cut-off agrees with new guidelines from
KDIGO [12]. When we considered a cut-off of ≥3 ml/
min/1.73 m2 in sensitivity analyses, we found a much lar-
ger proportion defined as having RP, weaker associations
with traditional renal risk factors, and less predictive abil-
ity with respect to future development of CKD. Addition-
ally, the KDIGO guidelines do not specify progression in
those without pre-existing CKD, which is the study popu-
lation included in this present analysis. Limiting the defin-
ition to those whose final eGFR is outside of the normal
range (i.e. <90 ml/min/1.73 m2) should hopefully ensure
that any changes in eGFR are clinically relevant.
RP definition A gave more consistent percentages than
RP definition B, where the percentage considered as RPs
varied from 0.4% to 4.5%, as shown in Figure 3, depending
on the length of follow-up and number of measurements
per year considered. Furthermore, a higher percentage
of those with RP under definition A progressed to CKDcompared to definition B. As RP definition A combines
absolute and average renal function decline, it is based on
all available eGFR and is less restrictive (in particular for
longer follow-up) and therefore may better reflect the dy-
namics of RP than definition B. One potential limitation
of our RP definition is that we did not base our definitions
on relative (percentage) changes. There have been sugges-
tions that a 25% decline from baseline in eGFR levels may
be an appropriate definition for RP [12].
For individuals with at least two eGFR measurements
per year, requirement of at least three years of follow-up
captures more eligible individuals into the RP analyses
compared to those with four years of follow-up, which
was the follow-up period considered in our original pri-
mary definition. Shorter periods of follow-up with more
included individuals are more likely to ensure a more in-
clusive study population and more statistical power to
identify associations. Clearly, the longer the follow-up
period, the more likely we are to introduce selection
bias, with those with the worst predicted outcome being
excluded if they had died or dropped out of the study
due to ill health. Therefore, the choice of two or three
years’ follow-up could be taken in an attempt to minim-
ise selection bias, although one cannot ever definitively
exclude this. Conversely, two years may be too short a
time period to permit accurate determination of RP,
therefore, three years appeared most suitable.
Requirement of three rather than two eGFR measure-
ments/year provides a more reliable slope and identifies
a greater proportion progressing to CKD. Two measure-
ments per year may however, be more applicable in rou-
tine clinical care, particularly as there is a move towards
less frequent laboratory monitoring of HIV positive indi-
viduals. In this study there was a median of three creatin-
ine measurements per individual per year, which means
that any definition of RP that requires three or more mea-
surements performed each year is unlikely to be oper-
ational due to high proportions being excluded.
In our definition of RP, the proportion of RPs who
progressed to CKD were ten–fold higher than non-RPs
who progressed to CKD, though the sensitivity for these
results were low, regardless of the definition used. This
suggests that RP is not necessarily predictive of incident
CKD, perhaps because treatment switches away from po-
tentially nephrotoxic drugs are made before incident CKD
has occurred [32] or because longer follow-up would be
needed to detect subsequent CKD events.
We used a small and selective number of variables, de-
fined a priori, to investigate their association with each of
our definitions of RP [23-29]. Our current analysis found
the strong association between age and hypertension with
RP when using our primary definition A. In contrast, it
was difficult to reach any conclusions for diabetes, where
associations were small or suggested a protective effect.
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made no changes to the results [10,17,19,21,28,31-33].
A composite endpoint of RP and all-cause mortality
provided more endpoints as expected, but a similar mag-
nitude of the association between age, hypertension and
diabetes. As very few deaths in HIV-positive individuals
were attributable to renal disease, including all-cause
mortality in the endpoint did not give a more sensible def-
inition of RP. Therefore, we would not recommend using
a combined endpoint of all-cause mortality and RP.
In this analysis we have not considered exposure to anti-
retroviral treatment, as our aim was not to study factors as-
sociated with RP, but rather to develop a definition of RP
that can be used in the future in such studies. Scherzer
et al. demonstrated that tenofovir use was associated
with rapid decline in renal function, where rapid decline
was defined as an annual decline of 3 ml/min/1.73 m2
for two consecutive years, but not specified if absolute or
average [18].
Sensitivity analyses with eGFR calculated from the
MDRD or CKD-EPI equations [35,36], were not carried
out, as both of these methods required ethnicity, which
some of the participating cohorts in the D:A:D study are
prohibited from collecting. However, recent studies have
suggestedthat consistent results are obtained regardless
of the estimation used [37,38], although other studies
have not found this [38-40]. Furthermore, the CG for-
mula was adjusted for BSA, in line with previous D:A:D
analyses [2] and there are conflicting reports regarding
whether this is appropriate [41,42]. Analyses performed
on this cohort on standardising for BSA suggests that it
has little impact on obtained eGFRs (Prof A Mocroft,
personal communication).
In the D:A:D study, no systematic information is col-
lected on proteinuria, which is a reliable marker for rapid
eGFR decline [31]. Furthermore, the C-Statistic values ob-
tained were in the range of 0.56 to 0.62 and so the ability
of the logistic model to discriminate between those with
and without RP would only be considered ‘satisfactory’
using Hosmer and Lemeshow’s criteria [43]. Using mul-
tiple endpoints with different length of follow-up and
number of measurements in order to identify a model that
best fits our selected variables associated with RP may lead
to us finding a false positive result.
Conclusions
In this analysis, we have developed a standardised oper-
ational definition for rapid progression of eGFR. We be-
lieve this definition balances practical issues regarding
the data likely to be available in standard HIV observa-
tional databases with a definition that has clinical rele-
vance. Under this definition, 3% of those with normal
eGFR went on to develop RP (definition A), and of these
5.4% (20/369) progressed to CKD during a median of5.6 years of follow-up, including the follow-up used to
define individuals as experiencing RP or not.
Despite the weak association between our RP defin-
ition and subsequent development of CKD, perhaps due
to the limited follow-up available, other studies have
shown that short-term changes in eGFR relate to subse-
quent mortality and underline the clinical importance of
RP. In future analyses, the D:A:D study group will con-
sider this definition of RP to identify and assess potential
risk factors including antiretroviral use, as a dynamic tool
to be used in addition to commonly used CKD analysis.Additional files
Additional file 1: Table S1. aBaseline characteristics of patients included
in analyses of rapid progression, according to availability of data.
Additional file 2: Table S2. Percentage who progressed to incident
CKD or death according to different definitions of RP.
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